BECTON DICKINSON & CO

Listed Company

BDXCIK 0000010795NYSELarge AcceleratedSurgical & Medical Instruments & ApparatusNew JerseyFY ends Sep 30

Period

FY 2025

Revenue

$21.84B

Net Income

$1.68B

Total Assets

$55.33B

Equity

$25.39B

Shares Out

284.74M

Op. Cash Flow

$3.43B

Business

BECTON DICKINSON & CO is a global medical technology company that develops, manufactures and sells a broad range of medical supplies, devices, laboratory equipment and diagnostic products for healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and consumers. Its main products and services include medication delivery and management systems, infection prevention products, surgical and interventional devices, diagnostic instruments and reagents, specimen and cell-analysis tools, and informatics and analytics solutions. BD organizes operations into five segments—Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences. The company markets and distributes products worldwide through direct sales, independent sales representatives and distributor channels across EMEA, Greater Asia, Latin America, Canada and the United States.

Summary from filing dated 2025-11-25

Financials

Consolidated Statement of Income

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Revenues	21,840	20,178	19,372	18,870	19,131
Cost of products sold	11,915	11,053	11,202	10,393	10,500
Selling and administrative expense	5,278	4,857	4,719	4,709	4,719
Research and development expense	1,265	1,190	1,237	1,256	1,279
Integration, restructuring and transaction expense	408	458	313	192	—
Other operating expense (income), net	396	222	−210	37	203
Total Operating Costs and Expenses	19,261	17,780	17,261	16,588	16,881
Operating Income	2,579	2,397	2,111	2,282	2,250
Interest expense	−613	−528	−452	−398	−469
Interest income	38	163	49	16	9
Other expense, net	−123	−28	−46	−117	−99
Income from Continuing Operations Before Income Taxes	1,881	2,005	1,662	1,783	1,692
Income tax provision	203	300	132	148	88
Net Income from Continuing Operations	1,678	1,705	1,530	1,635	1,604
Loss from Discontinued Operations, Net of Tax	0	0	−46	144	488
Net Income	1,678	1,705	1,484	1,779	2,092
Preferred stock dividends	0	0	−60	−90	−90
Net income applicable to common shareholders	1,678	1,705	1,424	1,689	2,002
Income (Loss) from Continuing Operations, Per Basic Share (in USD per share)	5.83	5.88	5.14	5.42	5.23
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share (in USD per share)	0	0	−0.16	0.5	1.69
Earnings Per Share, Basic	5.83	5.88	4.97	5.93	6.92
Income (Loss) from Continuing Operations, Per Diluted Share (in USD per share)	5.82	5.86	5.1	5.38	5.18
Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share (in USD per share)	0	0	−0.16	0.5	1.67
Diluted Earnings per Share (in USD per share)	5.82	5.86	4.94	5.88	6.85

Consolidated Balance Sheet

As of · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Cash and equivalents	641	1,717	1,416	1,006	2,283
Restricted cash	210	139	65	153	109
Short-term investments	8	445	8	8	12
Trade receivables, net	2,994	3,033	2,534	2,191	2,350
Inventories	3,894	3,843	3,273	3,224	2,743
Prepaid expenses and other	1,508	1,292	1,380	1,559	1,048
Total Current Assets	9,255	10,468	8,676	8,141	8,838
Property, Plant and Equipment, Net	6,997	6,821	6,557	6,012	6,003
Goodwill	26,612	26,465	24,522	24,621	23,886
Developed Technology, Net	6,651	7,733	8,058	9,108	9,417
Customer Relationships, Net	2,231	2,635	2,338	2,683	2,815
Other Intangibles, Net	523	549	552	519	541
Other Assets	3,056	2,615	2,078	1,848	1,945
Total Assets	55,325	57,286	52,780	52,934	53,866
Current debt obligations	1,560	2,170	1,141	2,179	500
Accounts payable	1,974	1,896	1,641	1,699	1,739
Accrued expenses	3,103	3,476	2,604	2,605	2,867
Salaries, wages and related items	1,346	1,246	1,115	1,171	1,186
Income taxes	329	168	139	157	178
Total Current Liabilities	8,313	8,956	6,641	7,811	6,626
Long-Term Debt	17,621	17,940	14,738	13,886	17,110
Long-Term Employee Benefit Obligations	1,069	942	1,023	902	1,228
Deferred Income Taxes and Other Liabilities	2,933	3,558	4,582	5,052	5,209
Commitments and Contingencies	—	—	—	—	—
Common Stock, Value, Issued	371	371	371	365	365
Capital in excess of par value	20,075	19,893	19,720	19,553	19,272
Retained earnings	16,622	16,139	15,535	15,157	13,826
Deferred compensation	25	25	24	23	23
Treasury Stock, Value	−9,808	−8,807	−8,305	−8,330	−7,723
Accumulated other comprehensive loss	−1,895	−1,732	−1,548	−1,488	−2,088
Total Shareholders Equity	25,390	25,890	25,796	25,282	23,677
Total Liabilities and Shareholders Equity	55,325	57,286	52,780	52,934	53,866

Consolidated Statement of Cash Flows

Year Ended · In millions, except per-share amounts

Concept	FY 2025 2025-09-30	FY 2024 2024-09-30	FY 2023 2023-09-30	FY 2022 2022-09-30	FY 2021 2021-09-30
Depreciation and amortization	2,462	2,286	2,288	2,229	2,230
Share-based compensation	258	247	259	233	229
Deferred income taxes	−474	−211	−622	−120	−301
Trade receivables, net	71	−453	−290	32	−61
Inventories	−410	98	−15	−631	−83
Prepaid expenses and other	−276	23	192	−436	−184
Accounts payable, income taxes and other liabilities	−185	625	−517	−473	660
Pension obligation	23	−70	112	−55	71
Gain on sale of business	0	0	−268	0	0
Product remediation-related charges	98	38	653	72	56
Other, net	186	−445	−332	−16	−470
Net Cash Provided by Continuing Operating Activities	3,430	3,844	2,990	2,471	4,126
Capital expenditures	−760	−725	−874	−973	−1,194
Maturities and sales (purchases) of investments, net	422	−421	0	—	—
Acquisitions, net of cash acquired	0	−3,924	0	−2,070	−508
Proceeds from divestitures, net	0	0	540	0	0
Other, net	−480	−444	−382	−178	−142
Net Cash Used for Investing Activities	−818	−5,514	−716	—	−1,880
Change in short-term debt	455	400	−230	230	0
Proceeds from long-term debt	0	4,517	1,662	497	4,869
Payments of debt	−1,789	−1,142	−2,155	−805	−5,112
Repurchase of common stock	−1,000	−500	0	−500	−1,750
Dividends paid	−1,196	−1,100	−1,114	−1,082	−1,048
Other, net	−87	−89	−120	−77	−265
Net Cash (Used for) Provided by Financing Activities	−3,617	2,087	−1,956	—	−3,306
Net Cash Used for Operating Activities of Discontinued Operations	0	−46	−1	163	521
Effect of exchange rate changes on cash and equivalents and restricted cash	0	4	5	−45	15
Net (Decrease) Increase in Cash and Equivalents and Restricted Cash	−1,005	375	322	−1,233	−525

Filings

Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro

Material Events

Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro

Insiders

Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro

Institutional Holders

Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro